IFB Health Economic Evaluations -2 Day Training: 31/01/2019-1/02/2019


It is well known that in the current health care context, efficacy and safety of medicines are no longer sufficient for successful market access. There is an increased need to provide “value for money”. The same is also valid for medical devices and diagnostics. Economic evaluations and Health Technology assessment (HTA) are key requirements in the development and use of “health care technologies” (drugs, medical devices, diagnostics). Such evaluations allow allocating available budgets to those treatments that provide the most health gain for each Euro invested.
The number of economic evaluations is steadily growing and more and more governments are explicitly requesting these evaluations during decision making processes on pricing and reimbursement.


Detailed program:


8.30h Reception with coffee

 Introduction to health economic evaluations - Lieven Annemans

  • Challenges of current health policies; why health economic evaluations.

  • Definitions and principles of health economic evaluations and Health Technology Assessment HTA.

  • Introduction to the QALY

  • Thresholds for Societal willingness to pay for Health Gains


 Methods for health economic evaluations - Lieven Annemans 

  • Health Economic models

  • Principles of cost analysis and budget impact analysis

  • The use of clinical trials in health economic evaluations



8.30h  Reception with coffee

Step by step exploration of a health economic analysis - Karen Moeremans

Practical example to apply the obtained knowledge from day 1. Exploration of a health economic model to make participants more familiar with health economic evaluations in daily practice:

  • study design
  • the steps required to complete a cost-utility and budget impact analysis
  • modelling methods
  • presentation and interpretation of results and sensitivity analyses 

Participants are requested to bring their laptop for exercises and exploration of the model in MS Excel.


Belgian guidelines for health economic evaluations and reporting (KCE) - Barbara Claus - CTG & Hospital pharmacist Ugent

With additional focus on contract negotiations.


Health economic evaluations and HTA in decision making on reimbursement issues and trends - Lieven Annemans


Your speakers / Faculty members: for more details see under


Lieven Annemans:

Lieven Annemans, PhD, MMan, MSc, Professor of health economics, Ghent University. Lieven Annemans is a Full Professor of Health Economics at Ghent University. He is Past President of ISPOR, the International Society for PharmacoEconomics and Outcomes Research, and ex-advisor to the Minister of Social Affairs. He has > 20 years of experience in health-economic evaluations of pharmaceutical drugs, vaccines, medical devices, diagnostics, and preventive health actions in various medical areas. His main research interests are epidemiological models, Health Technology Assessment, retrospective/prospective health-economic evaluations, and physician payment systems. He has published > 250 papers in peer-reviewed journals and has given hundreds of lectures and trainings on health-economic evaluation.
He is also author of the book “Health economics for non-economists: an introduction to the concepts, methods and pitfalls of health economic evaluations” (Academia Press; 2008.  - available in English, Dutch, French, Turkish and Russian). His other books "De prijs van uw gezondheid"  and "Je geld of je leven in de gezondheidszorg" show the difficulties of the Belgian Health Care system and proposed solutions. 

Karen Moeremans:

Managing partner and health economist at CHESS. Karen graduated as MD in 1993. Karen worked for several years in pharmaceutical industry as a CRA and medical advisor. Since 1998 Karen has been conducting and managing health economic projects, first as health scientist at HEDM, later as consultant, senior consultant and director of Health Economics and Outcomes Research (HEOR) at IMS Health Consulting. In 2013, Karen joined CHESS, a small-scale company striving to provide high quality-driven consulting services in health economic simulations and strategies. During these 20 years in health economics, Karen’s work has involved the management, conduct, supervision and quality assurance of HEOR projects, both at a national and international level. She gained experience in health economic evaluations in a wide range of disease areas such as oncology, hematological oncology, gynaecology, ophthalmology, dermatology, infectious diseases, psychiatric diseases, neurology, vaccines... . Her broad experience encompasses health economic modelling, cost-effectiveness and cost-utility evaluations, cost of illness studies, budget impact analysis…   At CHESS Karen is responsible for the conduct or the quality assurance of health economic projects which include performing cost-effectiveness and budget impact analyses for reimbursement dossiers, developing global economic models, performing technical model validations, …

Barbara Claus: Barbara Claus, PharmD, PhD

Barbara Claus is a hospital pharmacist (since 2002) and currently works at the Ghent University Hospital in Belgium. She is also substitute member of the CTG/ CRM.
She is a member of the pharmacotherapeutic committee and is responsible for the logistics and accurate use (clinical pharmacy) of drugs. She obtained her PhD in Medical Sciences in 2015 with a research topic in the domain of clinical pharmacy and pharmacoeconomics and is now visiting professor at the Faculty of Pharmaceutical Sciences and the Faculty of Medicine and Health Sciences at Ghent University.
In the previous years, she was a research member and author for several projects of the Federal Public Service of Health. She is a current member of the national policy group on drug shortages in Belgium.
Her past involvement as vice-president (2011-2012) and as president (2012-2014) of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Student Chapter of Belgium highlights her interest in efficient use of drugs. She currently leads the special interest group of pharmacoeconomics of the European Society of Clinical Pharmacy. 



This 2 day training will take place in Brussels (Grand-Bigard/ Groot-Bijgaarden) - Salons Waerboom and is non-residential. 






• The 2-day training::
o Seminar fee: 1.325 € (excl. VAT)
o Catering for 2 days  (excl.VAT including lunches, breaks,…): 155 € (excl. Vat)


Price reductions?

• IFB members receive a 5 % discount
• For non-profit organizations we offer a 50% discount.

KMO-portefeuille: Erkenningsnummer:  DV.O104106 / 2 x 8 hours

Only cancelations in writing will be accepted (mail, fax or email). In case of a written cancellation until three months before start of the course, only administrative charges (100 EURO) are billed. In case of cancellation between one and three months before start of the course 25% of the seminar fee remain payable. Cancelling within one month before, the full seminar fee needs to be paid. Absence of the participant, even by “Force Majeure”, does not entitle reimbursement. When the registered person is not able to attend for one or more sessions, it is possible to be replaced by a colleague/employee, only upon notification to the IFB secretariat.


Copyright © 2019, All rights reserved.